| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1269.5B | ¥1281.0B | -0.9% |
| Operating Income | ¥77.3B | ¥74.0B | +4.6% |
| Ordinary Income | ¥88.8B | ¥104.6B | -15.1% |
| Net Income | ¥40.4B | ¥57.5B | -29.7% |
| ROE | 2.0% | 2.9% | - |
FY2025 Q3 cumulative results: Revenue 126.9B yen (YoY -0.9%), Operating Income 7.7B yen (YoY +4.6%), Ordinary Income 8.9B yen (YoY -15.1%), Net Income 4.0B yen (YoY -29.7%). Revenue remained essentially flat while operating profit improved through cost management. However, ordinary and net income declined significantly due to reduced equity method gains and increased tax burden with an effective tax rate of approximately 46.8%. Operating margin expanded to 6.1% from 5.8% in the prior year, but net profit margin compressed to 3.2% from 4.5%, reflecting the substantial gap between operating performance and bottom-line results.
Revenue declined marginally by 1.2B yen (-0.9% YoY) to 126.9B yen, with segment performance showing mixed results. Industrial Process segment revenue decreased 1.7B yen (-3.1%) to 53.0B yen, while Visual Imaging segment remained stable at 60.6B yen (+0.2B yen, +0.3%). Life Science segment increased 0.2B yen (+5.5%) to 4.7B yen, and Photonics Solution segment grew 0.1B yen (+0.8%) to 7.7B yen. Despite flat revenue, operating income improved 0.3B yen (+4.6%) to 7.7B yen, driven by improved operating efficiency and cost control. The operating margin expanded 0.3pt from 5.8% to 6.1%, demonstrating operational leverage. Segment operating profit showed significant variance: Industrial Process segment profit declined 3.3B yen (-46.3%) to 3.8B yen, while Visual Imaging segment profit more than doubled, increasing 2.1B yen (+145.2%) to 3.6B yen. Life Science segment improved profitability by 1.0B yen to 0.2B yen operating income from prior year loss of 0.8B yen. Photonics Solution segment turned profitable with 0.2B yen operating income versus prior year loss of 0.3B yen. The material gap between ordinary income (8.9B yen) and operating income (7.7B yen) reflects net non-operating income of 1.1B yen, comprising interest and dividend income of 1.6B yen, foreign exchange gains of 1.2B yen, and equity method gains. The significant divergence between ordinary income (-15.1% YoY) and net income (-29.7% YoY) stems from non-recurring factors including investment securities sale gains of 3.5B yen offset by special losses of 4.9B yen, combined with elevated tax burden at effective rate of 46.8%. This represents a revenue flat/profit mixed pattern, with operating profit improving despite revenue headwinds, while bottom-line profits compressed due to higher taxes and special items.
Industrial Process segment generated revenue of 53.0B yen (41.7% of total) with operating income of 3.8B yen (operating margin 7.2%), representing the largest segment by scale and serving as core business despite YoY profit decline of 46.3%. Visual Imaging segment recorded revenue of 60.6B yen (47.8% of total) with operating income of 3.6B yen (operating margin 5.9%), showing strong profit recovery with operating income more than doubling YoY (+145.2%). Life Science segment achieved revenue of 4.7B yen (3.7% of total) with operating income of 0.2B yen (operating margin 4.4%), successfully turning profitable from prior year operating loss of 0.8B yen. Photonics Solution segment posted revenue of 7.7B yen (6.1% of total) with operating income of 0.2B yen (operating margin 3.2%), also achieving profitability turnaround from prior year loss of 0.3B yen. Margin differences between segments are material, with Industrial Process maintaining highest operating margin at 7.2%, while Photonics Solution operates at lowest margin of 3.2%. The shift in profit contribution from Industrial Process dominance to more balanced contribution across Visual Imaging and Industrial Process indicates improving portfolio diversification.
[Profitability] ROE of 2.0% declined from prior year levels, reflecting compressed net profit margin of 3.2% (down from 4.5% YoY) due to elevated tax burden and special losses, while operating margin improved 0.3pt to 6.1% from 5.8% YoY. ROA of 1.3% and ROIC of 2.6% both remained at low single-digit levels, indicating room for improvement in capital efficiency. [Cash Quality] Cash and equivalents of 70.1B yen provide robust liquidity coverage, with cash representing 22.3% of total assets. Short-term debt coverage stands at 47.7x based on cash holdings of 70.1B yen against short-term borrowings of 1.5B yen. Investment securities holdings of 44.0B yen supplement financial flexibility. [Investment Efficiency] Asset turnover of 0.40 times remains below typical manufacturing levels, with inventory turnover extended to 353 days (DIO) and receivables collection at 103 days (DSO), resulting in cash conversion cycle of 373 days that warrants monitoring for working capital optimization. [Financial Health] Equity ratio of 62.8% compares favorably to prior period 67.4%, with total equity of 197.9B yen against total assets of 315.0B yen. Current ratio of 258.1% and quick ratio of 217.7% demonstrate strong liquidity position. Debt-to-equity ratio of 0.14 and interest-bearing debt of 28.0B yen relative to equity indicate conservative financial leverage.
Cash and deposits increased 0.6B yen YoY to 70.1B yen, while total assets expanded 17.6B yen to 315.0B yen, indicating capital deployment into operating assets. Investment securities holdings increased 2.3B yen to 44.0B yen, reflecting continued financial asset accumulation. Working capital dynamics show accounts receivable declining 4.5B yen to 48.5B yen, improving from 53.0B yen in prior year, while inventories increased 1.1B yen to 122.6B yen from 121.5B yen. Accounts payable decreased 2.1B yen to 37.3B yen from 39.4B yen, suggesting reduced supplier credit utilization. The combination of higher inventory levels and lower payables indicates working capital consumption despite improved receivables management. Fixed assets increased 16.9B yen to 131.0B yen, suggesting capital investment activity. Contract liabilities of 14.6B yen represent advance customer payments providing operational funding. The cash coverage of short-term liabilities stands at 9.1% based on cash of 70.1B yen against current liabilities of 76.7B yen, while overall liquidity position remains adequate with current assets of 197.8B yen covering current liabilities by 2.6x.
Ordinary income of 8.9B yen versus operating income of 7.7B yen shows net non-operating contribution of approximately 1.1B yen, representing 0.9% of revenue. Non-operating income comprises primarily interest and dividend income of 1.6B yen and foreign exchange gains of 1.2B yen as primary components, partially offset by interest expenses of 0.3B yen. Special items show investment securities sale gains of 3.5B yen offset by special losses of 4.9B yen including restructuring costs, resulting in net special loss of 1.3B yen that impacts earnings quality as non-recurring factor. The effective tax rate of 46.8% significantly exceeds standard corporate rates, with tax expense of 4.0B yen against pre-tax income of 7.6B yen, suggesting deferred tax impacts or non-deductible items affecting reported earnings quality. Non-operating income represents 1.3% of revenue as modest contribution relative to operating performance. While operating cash flow data is not available for quarterly reporting, balance sheet analysis indicates working capital deterioration with extended inventory days and cash conversion cycle, suggesting potential divergence between accrual earnings and cash generation that warrants monitoring.
Full-year guidance targets revenue of 170.0B yen, operating income of 10.0B yen, ordinary income of 10.5B yen, and net income of 7.0B yen. Q3 cumulative progress rates show revenue achievement of 74.7% (126.9B yen of 170.0B yen target), operating income at 77.3% (7.7B yen of 10.0B yen), ordinary income at 84.5% (8.9B yen of 10.5B yen), and net income at 57.7% (4.0B yen of 7.0B yen). Against standard Q3 progress expectation of 75%, revenue and operating income track in line with seasonal patterns. Ordinary income progress of 84.5% exceeds standard pace by 9.5pt, while net income progress of 57.7% falls short by 17.3pt, primarily due to the elevated tax burden in Q3. The significant gap in net income progress suggests either expected tax normalization or additional profit contribution in Q4 to achieve full-year guidance. The company maintained its full-year outlook despite Q3 bottom-line underperformance, implying confidence in Q4 recovery through improved tax position and absence of special losses.
Annual dividend of 70 yen per share is planned for fiscal year end. Payout ratio based on current net income of 4.0B yen and forecasted annual dividend totals to approximately 6.1B yen (assuming approximately 87 million shares outstanding based on EPS guidance of 79.45 yen), resulting in payout ratio of 153% versus current period net income, which exceeds 100% threshold. When measured against full-year net income guidance of 7.0B yen, the implied payout ratio normalizes to approximately 87%, suggesting the company expects improved profitability in Q4 to support dividend sustainability. Treasury stock increased significantly by 14.5B yen from 7.7B yen to 22.2B yen, indicating share buyback activity during the period. The combination of dividend payments and treasury stock acquisitions demonstrates active shareholder return policy, though the elevated payout ratio relative to current period earnings warrants attention to sustainability against cash generation and working capital needs.
Revenue concentration in Industrial Process and Visual Imaging segments creates dependency risk, with these two segments representing 89.5% of total revenue. The Industrial Process segment experienced significant profit decline of 46.3% YoY despite revenue declining only 3.1%, indicating operating leverage sensitivity to volume changes. Working capital inefficiency poses cash flow risk, with inventory days of 353 and cash conversion cycle of 373 days substantially exceeding manufacturing industry norms, potentially constraining operating cash generation. The effective tax rate of 46.8% significantly exceeds statutory rates, creating earnings volatility risk if tax positions fluctuate or one-time tax impacts persist.
[Industry Position] (Reference - Proprietary Analysis) The company's operating margin of 6.1% falls below the manufacturing industry median of 8.3% (Q3 2025, n=98 companies), indicating room for improvement in operational efficiency relative to peers. Net profit margin of 3.2% also trails the industry median of 6.3%, reflecting both lower operating margins and higher tax burden. ROE of 2.0% substantially underperforms the industry median of 5.0%, positioning in the lower quartile of manufacturing sector profitability. Equity ratio of 62.8% aligns closely with industry median of 63.8%, demonstrating comparable financial conservatism. Asset turnover of 0.40 falls below industry median of 0.58, consistent with extended working capital cycle. Current ratio of 258.1% significantly exceeds industry median of 2.84x, reflecting strong but potentially excess liquidity. Inventory turnover of 353 days substantially exceeds industry median of 109 days (IQR: 50-155 days), representing material working capital inefficiency. Revenue growth of -0.9% underperforms industry median growth of +2.7%, while operating margin expansion provides partial offset to top-line headwinds. (Industry: Manufacturing, n=98 companies, Comparison: FY2025 Q3, Source: Proprietary analysis)
Operating performance demonstrated resilience with margin expansion to 6.1% despite revenue headwinds, driven by successful cost management and segment profit recovery in Visual Imaging, Life Science, and Photonics Solution businesses that offset Industrial Process weakness. Balance sheet strength remains intact with equity ratio of 62.8%, minimal financial leverage (D/E 0.14), and robust liquidity (current ratio 258%), providing financial flexibility for strategic investments and shareholder returns despite near-term earnings pressure. Working capital management emerges as critical focus area, with inventory days of 353 and cash conversion cycle of 373 days substantially exceeding industry benchmarks, indicating significant opportunity for cash generation improvement through operational discipline in inventory and receivables management that could enhance returns on invested capital from current 2.6% level.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.